NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, October 29th. Stockholders of record on Friday, November 8th will be paid a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, November 7th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) announced its quarterly earnings data on Tuesday, October, 29th. The biotechnology company reported $1.06 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.14. The biotechnology company had revenue of $183.24 million for the quarter, compared to the consensus estimate of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.98 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 brokers have issued twelve-month price targets for BIO-TECHNE's stock. Their forecasts range from $179.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $231.50 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Press coverage about TECH stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIO-TECHNE earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 418,000 shares, an increase of 12.7% from the December 31st total of 370,900 shares. Based on an average trading volume of 119,500 shares, the days-to-cover ratio is currently 3.5 days. Approximately 1.1% of the shares of the stock are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), NVIDIA (NVDA), General Electric (GE), Global Medical REIT (GMRE), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Ionis Pharmaceuticals (IONS).

BIO-TECHNE's stock is owned by a number of of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (1.02%), Conestoga Capital Advisors LLC (0.84%), Candriam Luxembourg S.C.A. (0.45%), Retirement Systems of Alabama (0.24%), California Public Employees Retirement System (0.23%) and Summit Creek Advisors LLC (0.22%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Conestoga Capital Advisors LLC, Arizona State Retirement System, Dupont Capital Management Corp, State of Alaska Department of Revenue, Tributary Capital Management LLC, New York State Teachers Retirement System and Summit Creek Advisors LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., California Public Employees Retirement System, Mckinley Capital Management LLC Delaware, Campbell & CO Investment Adviser LLC, Virginia Retirement Systems ET AL, Tocqueville Asset Management L.P. and Hardy Reed LLC. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $218.43.

BIO-TECHNE has a market capitalization of $8.32 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]